Angelini Pharma

Executive Summary

Angelini Pharma, a privately-held Italian pharmaceutical company with over a century of heritage, is dedicated to advancing health solutions across Brain Health (including Mental Health and Epilepsy), Specialty and Primary Care, and Consumer Healthcare. With its headquarters in Rome, the company leverages a diversified portfolio and a strong European presence to address unmet medical needs. Angelini's commitment to innovation is evident in its focus on developing therapies for neurological and psychiatric disorders, a therapeutic area with significant demand growth due to aging populations and increasing awareness of mental health. The company's integrated model, spanning prescription drugs, over-the-counter products, and consumer health, provides revenue stability and cross-segment synergies. While Angelini operates primarily in Europe, its strategic partnerships and licensing agreements enable expansion into emerging markets, positioning it for steady growth in a competitive landscape. As a private entity, Angelini Pharma does not disclose detailed financials or pipeline timelines, limiting visibility into near-term catalysts. However, key anticipated developments include potential regulatory approvals for its late-stage brain health assets, particularly in epilepsy and depression, which could strengthen its market position. Additionally, the company may pursue strategic collaborations or acquisitions to bolster its specialty care portfolio, especially in high-growth areas like CNS disorders. Lastly, expansion of its consumer healthcare segment into new geographies could drive revenue diversification. These catalysts, while uncertain, align with Angelini's strategic priorities and the evolving pharmaceutical landscape. Given the company's established reputation and diversified operations, it maintains a moderate conviction for near-term value creation.

Upcoming Catalysts (preview)

• Q3 2026Potential regulatory approval for a new epilepsy treatment in Europe60% success
• TBDAnnouncement of a strategic partnership or licensing deal in CNS40% success
• Q2 2026Expansion of consumer healthcare product line into new European markets70% success